Clinical Trial: Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis—a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Tr

Brief Summary: -Evaluate the efficacy and safety of Shenyankangfu Tablets to control the proteinuria of patients with primary glomerulonephritis compare with Losartan potassium.

Detailed Summary:
Sponsor: Chinese PLA General Hospital

Current Primary Outcome: changes of 24 hours proteinuria after the treatment [ Time Frame: 0,4,8,12,24,36,48 weeks after the enrollment ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • changes of serum creatinine after treatment [ Time Frame: 0,4,8,12,24,36,48 weeks after the enrollment ]
  • changes of eGFR after the treatment [ Time Frame: 0,4,8,12,24,36,48 weeks after the enrollment ]
  • changes of Traditional Chinese Medicine syndrome scores after the treatment [ Time Frame: 0,4,8,12,24,36,48 weeks after the enrollment ]


Original Secondary Outcome:

  • changes of serum creatinine after treatment [ Time Frame: 0,4,8,12,24,36,48 weeks after the enrollment albumin ]
  • changes of eGFR after the treatment [ Time Frame: 0,4,8,12,24,36,48 weeks after the enrollment ]
  • changes of Traditional Chinese Medicine syndrome scores after the treatment [ Time Frame: 0,4,8,12,24,36,48 weeks after the enrollment ]


Information By: Chinese PLA General Hospital

Dates:
Date Received: February 12, 2014
Date Started: February 2014
Date Completion:
Last Updated: June 29, 2015
Last Verified: June 2015